9th Annual Cell Line Development and Engineering Asia – Agenda

Day 1: 8 July 2020

0800
Conference Registration & Morning Coffee


BDP China 2020 Joint Opening Plenary Sessions


0900
Chairperson’s Opening Remarks

0910
OPENING ADDRESS
China’s Big Leap towards BioPharma 2030– Innovation, Industrialization, Internationalization

Dr. Song Rulin, Executive President, China Pharmaceutical Innovation and Research Development Association (PhIRDA), China

0930
KEYNOTE ADDRESS
China’s Biologics Facilities for the Future – WuXi’s Story on Technology and Innovation

Dr. Chris Chen, Chief Executive Officer, WuXi Biologics, China

0950
Manufacturers’ Panel:
New Therapies, New Tech and New Investment

  • New frontiers in drug development
  • What is the gap in quality and investment?
  • Embracing new tech and start-ups to drive progress
  • New therapeutics manufacturing, commercialization and global access
  • Biomanufacturing 4.0 – Where are we at?
  • DAL’s GAMP and licensing laws – How is it affecting our business and what can we expect?
  • The GQCE framework – Quality consistency and better pricing

Confirmed Panelists:
Jerry Su, Chief Executive Officer, Zhejiang Huahai Biopharmaceuticals, China
Wu Yifang, Chief Executive Officer, Fosun Pharma, China*
Larry Zhang, President, CASI Pharmaceuticals, China*
Glenn Hassan
, Chief Finance Officer, Chief Business Officer, CANbridge Pharmaceuticals, China
More panelists to be confirmed

1030
Morning Networking & Refreshment Break


9th Annual Cell Line Development & Engineering Asia Commences


11.00AM
Chairperson’s Opening Remarks

Dr. Orit Aharonovitz, Senior Director, Cell Line & Process Development, Teva Pharmaceuticals, IsraelThe State-of-Play for CLD

11.10AM
OPENING KEYNOTE
Optimising Cell Line Development: Applications for Furthering Biopharma R&D Strategy

  • Partnerships and ventures for furthering biopharma R&D capabilities and strategies

Dr. Orit Aharonovitz, Senior Director, Cell Line & Process Development, Teva Pharmaceuticals, Israel

11.40AM
Enhancing Complex Protein Expression with Highly-Efficient Gene Integration Technology

Senior Representative from Lonza

12.10PM
Networking Lunch


Novel Advances in CLD Techniques & Technology


1.10PM
Novel Transposases in Accelerating Cell Line Development

Dr. Claes Gustafsson, Chief Commercial Officer and Co-Founder, ATUM, U.S.

1.40PM
Efficient Cell Lines and Technology Applications

Lisa Zheng, Executive Director, Cell Line Development, Transcenta, China

2.10PM
Developing a New CLD Process from Ground-Up

  • Navigating the complex landscape of strategies for generating new cell lines
  • From DNA to lead clones, what new technologies and core instrumentation may impact future protein expression and cell line development campaigns?

Mark Stockdale, Amalgamator of Business and Biology, Solentim, U.K.

2.40PM
Whole-Genome Sequencing with Bioinformatics Tools for CHO Cell Lines

Senior Representative from Selexis

3.10PM
Afternoon Networking Break & Tea

3.40PM
High-Throughput Cloning Screening and Performance for Next-Generation Innovative Therapeutics

Ting Chen, Director, Alphamab Oncology, China

4.10PM
Precise Cell Processing and Workflow Automation in CLD

Senior Representative from Berkeley Lights

4.40PM
Industry Panel: Utilising Platform Technologies for CLD

  • Navigating the systems and various methods to accomplish their goals; comparing and contrasting tools
  • Case study-focused
  • Dealing with the flow and generation of high-throughput data and information
  • The Biopharma 4.0 paradigm for CLD: digital twins, applications of big data and tech developments for cell culture processes

Panelists:
Dr. Orit Aharonovitz, Senior Director, Cell Line & Process Development, Teva Pharmaceuticals, Israel
Xi Chen, Director, Cell Engineering, Qilu Pharmaceuticals, China
Eric Chang, Head, Cell Line Development, JHL Biotech, China
Lisa Zheng, Executive Director, Cell Line Development, Transcenta, China

5.20PM
End of Conference Day 1

*Please note that conference agenda and timing are subjected to change according to market development.

Day 2: 9 July 2020

0800
Morning Coffee


BDP China 2020 Joint Opening Plenary Sessions


0900
Chairperson’s Opening Remarks

0910
Keynote Address:
China’s Biopharma Capital Markets – Future Funds and Innovative Financing

Fu Wei, Chief Executive Officer, CBC Group, China

0940
Venture Capitals Roundtable: Show Me the Drug

  • Investment landscape of Chinese biopharma market
  • Evaluating drug pipelines and development prospects
  • Mergers, expansion and JVs – Where do we see transactions picking up?
  • Financing new plants, new therapeutics, product launch and scaling-up operations – How do we review?
  • Manufacturing 4.0 – How do VCs and banks play a part in modernising the value chain?

Panelists:
Rani Jarkas, Chairman, Cedrus Investments, Hong Kong
Judith Li, Partner, Lilly Asia Ventures, China
Dr. Karen Liu, Founding Partner, 3E Bioventures Capital, China
Lynn Yang, Managing Director, Sequoia Capital, China
Dr. John Zhu, Partner, 6 Dimensions Capital, China
More panellists to be confirmed

1000
Morning Networking & Refreshment Break


9th Annual Cell Line Development & Engineering Asia Commences


10.30AM
Chairperson’s Opening Remarks

Dr. Song Zhiwei, Principal Scientist, Bioprocessing Technology Institute, Singapore


Engineering Host Cell Lines, Genomics & CRISPR in Focus


10.40AM
Advances in Glycosylation and Expression Vectors for Recombinant Proteins

Dr. Song Zhiwei, Principal Scientist, Bioprocessing Technology Institute, Singapore

11:10AM
Applications for Glycan Analysis Workflows and Bioanalytical Proteins

Senior Representative from ProZyme

11.40AM
CRISPR in Cell Line Development:
Applications of CRISPR in Rapid Development of Stable Transgene CHO Cell Lines

Dr. Zhu Jianwei, Professor and Director of MOE Engineering Research Center of Cell Engineering and Antibody, Shanghai Jiaotong University; CEO and Chief Scientist, Jecho Biopharmaceuticals, China

12:10PM
Networking Lunch

1.10PM
Next-Generation Cell Line Engineering for Biopharmaceutical Production

  • Advancing microRNA to optimize and boost productivity of cell line growth
  • Use cases and applications of CRISPR/Cas9-mediated knockout for enhanced titre
  • Identifying bottlenecks in CLD: a streamlined and high-throughput approach

Dr. Kerstin Otte, Professor, Institute of Applied Biotechnology, Biberach University of Applied Sciences, Germany


Optimising Workflows and Bioprocesses


1.40PM
Integrated Cell Line Development Strategy in Whole CMC Picture

  • How to evaluate a CHO based expression systems?
  • Can the cell line generation work be integrated with other process?
  • How to achieve cell lines with high quality and stability under fast workflow?

Xi Chen, Director, Cell Engineering, Qilu Pharmaceuticals, China

2.10PM
Panel Discussion: What’s Next in the Future of CLD&E

  • What is the next thing in medicine that we will need to produce?
  • A look ATMPs, tissue generation, stem cells, exosomes and more
  • The landscape for CRISPR: how ready or willing is the industry to use CRISPR for cell line engineering?

Panelists:
Dr. Zhu Jianwei, Professor and Director of MOE Engineering Research Center of Cell Engineering and Antibody, Shanghai Jiaotong University; CEO and Chief Scientist, Jecho Biopharmaceuticals, China
Dr. Kerstin Otte, Professor, Institute of Applied Biotechnology, Biberach University of Applied Sciences, Germany
Dr. Song Zhiwei, Principal Scientist, Bioprocessing Technology Institute, Singapore

2.50PM
Afternoon Networking & Refreshment Break

3.20PM
Exploring the Synergies between Engineered Host Cells and Process Development

Eric Chang, Head, Cell Line Development, JHL Biotech, China

3.50PM
Outsourcing and Insourcing of CLD: End-User Perspectives and Commercial ROI

Senior Representative from TOT Biopharma, China

4.20PM
A Fully-Integrated Platform Approach for Highly-Quality CLD

  • Case study in Henlius’ in-house capabilities across the entire biologics value chain spanning across:
  • High-titer cell lines;
  • Proprietary cell culture production; and
  • Continuous manufacturing process for commercial production

Senior Representative from Shanghai Henlius Biotech, China

4.50PM
Accelerating CLD for Commercial Success

Dr. Pan Zhiwei, Senior Director, Process Development, Junshi Pharma, China

5.20PM
End of Conference

*Please note that conference agenda and timing are subjected to change according to market development.